We are recruiting for a newly established DFG Emmy Noether Research Group at the Division of Pediatric Hematology and Oncology, University Medical Center Freiburg, working at the interface of leukemia biology, translational metabolomics and ribosome profiling. The group is embedded in a high-profile collaborative environment spanning the DKTK (German Cancer Consortium) partner site Freiburg and DKFZ Heidelberg. This environment offers an exceptional platform to build a strong scientific profile in translational AML research.
Our research addresses one of the unmet clinical needs in oncology: understanding how acute myeloid leukemia (AML) cells survive and persist under therapeutic stress, and how this chemoresistance can be therapeutically disrupted. Using cutting-edge approaches including ribosome profiling, single-cell analysis, metabolomics, in vivo models and patient-derived xenografts (PDX), we dissect the metabolic and translational programs that drive treatment resistance and clonal heterogeneity in AML, in close collaboration with leading national and international partners in the field.
We are looking for an outstanding and highly motivated postdoctoral researcher who wants to take a leading role in shaping this research program, with the opportunity to develop their scientific profile, mentor doctoral students, and contribute to important publications.
